Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis-Reference-Cited by-同舟云学术

Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis

Published:2018-11-28 Issue:suppl_3 Volume:67 Page:S293-S302
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Deshpande Devyani¹,Pasipanodya Jotam G¹,Mpagama Stellah G²,Bendet Paula¹,Srivastava Shashikant¹,Koeuth Thearith¹,Lee Pooi S¹,Bhavnani Sujata M³,Ambrose Paul G³,Thwaites Guy⁴⁵,Heysell Scott K⁶,Gumbo Tawanda¹^ORCID

Affiliation:

1. Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas

2. Kibong’oto Infectious Diseases Hospital, Sanya Juu, Tanzania

3. Institute for Clinical Pharmacodynamics, Schenectady, New York

4. Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, Churchill Hospital, Oxford, United Kingdom

5. Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam

6. Division of Infectious Diseases and International Health, University of Virginia, Charlottesville

Funder

National Institutes of Health

National Institute of Allergy and Infectious Diseases

Baylor Research Institute

Wellcome Trust, UK

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/67/suppl_3/S293/26826604/ciy611.pdf

Reference50 articles.

1. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling;Gumbo;J Infect Dis,2004

2. The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations;Drusano;Clin Infect Dis,2006

3. Sensitivity of common marmosets to detect drug-induced QT interval prolongation: moxifloxacin case study;Komatsu;J Pharmacol Toxicol Methods,2010

4. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy;Shandil;Antimicrob Agents Chemother,2007

5. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance;Gumbo;Antimicrob Agents Chemother,2005

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic drug monitoring in tuberculosis;European Journal of Clinical Pharmacology;2024-09-06

2. Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis;Journal of Clinical Tuberculosis and Other Mycobacterial Diseases;2024-08

3. Construction of double Z-scheme Ag3PO4/MOF-In2S3/Bi2S3 heterojunction by micro-Ag bridges for photocatalytic degradation of levofloxacin;Applied Surface Science;2024-03

4. Respiratory fluoroquinolones in the treatment of specific and non-specific lung diseases (literature review);Vrach;2024-02-02

5. Push forward LC-MS-based therapeutic drug monitoring and pharmacometabolomics for anti-tuberculosis precision dosing and comprehensive clinical management;Journal of Pharmaceutical Analysis;2024-01